secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2023-09-13T23:59:59+00:00
Accession:  0001178913-23-003142
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio shareholders approve all proposals at 2023 annual meeting
--------------------------------------------------------------------

- Directors Lieberman, Ostrov, and Ellis elected with over 11.2M votes for each.
- Compensation items for CEO Toledano and Director Taitel ratified by large majorities.
- Board authorized to effect reverse share split (5:1 to 11:1) by Sept 2024 if needed.
- Kesselman & Kesselman (PwC) ratified as independent auditor for FY 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891323003142/0001178913-23-003142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891323003142/zk2330296.htm
  HTML page:      https://secwatch.observer/filing/0001178913-23-003142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer